
FDA Cancels Cipla Unit's Drug Licence Over Reactin Plus Irregularities
The story in brief
The Maharashtra Food and Drug Administration cancelled the drug sale licence of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding unit in Pune due to serious irregularities with Reactin Plus Tablets. These included improper storage, discrepancies in records, and unauthorised advertising. The FDA seized stock worth Rs 11.19 lakh and ordered a recall, while the company contested the order, stating it does not raise safety or efficacy concerns.